CD37 and B-cell non-Hodgkin lymphoma: Overall, the results of their studies showed that CD37 CAR-T cells could be used to eradicate those B-cell lymphoma tumors in which CD19 antigen expression has been lost, and after further investigation for patients with R/R B- NHL (229).